| 摘要 |
The composition of levosimendan ([[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile) and alginic acid is formulated for oral administration, in the form of tablets, dragees, capsules, powders or granules. The amount of levosimendan in the composition is from 0.1 to 20 % per weight of the composition, and the amount of alginic acid is preferably 10-40 % per weight of the composition.
|
